Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Three projects at Oxford have received funding from NIHR to assess breathlessness in Long COVID patients, investigate the impact of Long COVID on families, and examine the role of vaccines in Long COVID.

Illustration of SARS-CoV-2 viruses, the causative agent of COVID-19

People experiencing Long COVID will benefit from a comprehensive package of new NIHR-funded research to help improve understanding of the condition, from diagnosis and treatment through to rehabilitation and recovery. 15 projects from across the UK have been awarded a total of £19.6 million to examine causes of Long COVID, trial drugs to tackle it, and investigate symptoms such as breathlessness and ‘brain fog’ that have become synonymous with the condition. Studies will also evaluate health services, such as Long COVID clinics, and explore ways patients can monitor the condition to optimise their recovery and return to work.

Read the full story on the University of Oxford website.

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.